All Stories

  1. Why auto‐anti‐D might be more likely than allo‐anti‐D for people with conventional D type
  2. JK*01(307C) encodes a JK null allele
  3. Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID‐19 restriction in March 2020
  4. International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology Report of Basel and three virtual business meetings: Update on blood group systems
  5. A case of Tn polyagglutination discovered by an ABO blood group discrepancy
  6. Molecular blood group screening in Omani blood donors
  7. Generation of ‘designer erythroblasts’ lacking one or more blood group systems from CRISPR/Cas9 gene‐edited human‐induced pluripotent stem cells
  8. Novel KEL*02N allele in Saudi Arabia encoding a Kell null (K0) phenotype
  9. A pair of S‐silencing single nucleotide variants cis‐linked on GYPB
  10. Red cell genotyping of rare blood donors: donation behaviour and data visualization
  11. SCAR : The high‐prevalence antigen 013.008 in the Scianna blood group system
  12. Predictive modeling of complex ABO glycan phenotypes by lectin microarrays
  13. Anti‐D selection for D assignment among pregnant women and blood donors: impact of the Crawford antigen
  14. Complement activating ABO anti-A IgM/IgG act synergistically to cause erythrophagocytosis: implications among minor ABO incompatible transfusions
  15. Complement activating ABO IgM/IgG act synergistically to cause erythrophagocytosis: implications among minor ABO incompatible platelet transfusions
  16. It's time to phase out “serologic weak D phenotype” and resolve D types with RHD genotyping including weak D type 4
  17. ABO titers: harmonization and identifying clinically relevant ABO antibodies
  18. Fetal inheritance of GP*Mur causing severe HDFN in an unrecognized case of maternal alloimmunization
  19. IgG3 anti‐Kell allotypic variation results in differential antigen binding and phagocytosis
  20. How to use a cloud‐based search engine of a centralized donor database to identify historical antigen‐negative units in hospital inventories
  21. Use of a cloud‐based search engine of a centralized donor database to identify historical antigen‐negative units in hospital inventories
  22. Performance and reliability of a benchtop automated instrument for transfusion testing: a comparative multicenter clinical study in the US population
  23. Mass-scale red cell genotyping of blood donors: from data visualization to historical antigen labeling and donor recruitment
  24. New RHCE*ce variant allele in African descent holds 105C > T (silent) in cis to 48C in Exon 1 and 733G in Exon 5
  25. Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline
  26. Acquired red cell defects of the regulators of complement activation.
  27. Trends in antigen-negative red blood cell distributions by racial or ethnic groups in the United States
  28. The first reported case of concurrent trimethoprim-sulfamethoxazole-induced immune hemolytic anemia and thrombocytopenia
  29. 2015 conference on blood group genetics in the era of precision medicine.
  30. How do I work up pretransfusion samples containing anti-CD38?
  31. Genetic background of the rare Yus and Gerbich blood group phenotypes: homologous regions of the GYPC gene contribute to deletion alleles
  32. Molecular characterization of three novel weak D type alleles with additional haplotype data on weak D Types 1.2 and 18
  33. Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy
  34. Cost-effectiveness of implementing molecular immunohematology
  35. TheDAUcluster: a comparative analysis of 18RHDalleles, some forming partial D antigens
  36. Unusual serological findings associated with ceftriaxone-induced immune hemolytic anemia in a child with disseminated low-grade glioma
  37. RHCE*cE94Gencodes variable expression of c (RH4)
  38. Integration of red cell genotyping into the blood supply chain: a population-based study
  39. Implementing mass-scale red cell genotyping at a blood center
  40. A multicenter study on the performance of a fully automated, walk-away high-throughput analyzer for pretransfusion testing in the US population
  41. Barriers to using molecularly typed minority red blood cell donors in support of chronically transfused adult patients with sickle cell disease
  42. The future of red blood cell alloimmunization risk reduction
  43. It's time to phase inRHDgenotyping for patients with a serologic weak D phenotype
  44. RhD Specific Antibodies Are Not Detectable in HLA-DRB11501*Mice Challenged with Human RhD Positive Erythrocytes
  45. Prospects for the provision of genotyped blood for transfusion
  46. Antibody‐mediated glycophorin C coligation on K562 cells induces phosphatidylserine exposure and cell death in an atypical apoptotic process
  47. Allo- and autoanti-D in weak D types and in partial D
  48. Microfluidic approach to genotyping human platelet antigens
  49. Mass-scale high-throughput multiplex polymerase chain reaction for human platelet antigen single-nucleotide polymorphisms screening of apheresis platelet donors
  50. DNA-based methods in the immunohematology reference laboratory
  51. Editorial Comment
  52. Molecular basis of blood group expression
  53. Mass-scale red cell genotyping of blood donors
  54. Titers of ABO antibodies in group O blood donors
  55. Anti-glycophorin C induces mitochondrial membrane depolarization and a loss of extracellular regulated kinase 1/2 protein kinase activity that is prevented by pretreatment with cytochalasin D: implications for hemolytic disease of the fetus and newborn ca
  56. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?
  57. The proximal cis-regulatory region of theRHD/RHCEpromoter is 105 bp and contains a 55-bp core devoid of known binding motifs but necessary for transcription
  58. Genotyping for red blood cell polymorphisms
  59. Single Base Extension in Multiplex Blood Group Genotyping
  60. Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time
  61. Hemolytic Disease of the Fetus and Newborn Due to Anti-Ge3: Combined Antibody-Dependent Hemolysis and Erythroid Precursor Cell Growth Inhibition
  62. IFN-γ treated monocyte/macrophage phagocytosis of red cells sensitized with IgG1 and IgG3 Anti-D containing identical immunoglobulin variable region genes
  63. The Development of a Bacteriophage Expression Vector for Cloning Immunoglobulin Variable Region Genes from B-Cell Genomic DNAa
  64. Rh discrepancies caused by variable reactivity of partial and weak D types with different serologic techniques
  65. On the Complexity of D Antigen Typing: A Handy Decision Tree in the Age of Molecular Blood Group Diagnostics
  66. Fetal blood group genotyping
  67. Small world – Advance of microarrays: Current status and future trends
  68. The above letter was sent to Branch et al.; Drs Branch and Denomme offered the following reply.
  69. Predictive blood group genetics in hemolytic disease of the fetus and newborn: a 10-year review of a laboratory evaluation of amniotic fluid-derived DNA
  70. Detection of antibodies reacting with the antithetical duffy blood group antigens Fya and Fyb using recombinant fusion proteins containing the duffy extracellular domain
  71. Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-β and prostaglandin E2
  72. Inhibition of erythroid progenitor cell growth by anti-Ge3
  73. Amino-acid substitution in the disordered loop of blood group B-glycosyltransferase enzyme causes weak B phenotype
  74. High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes
  75. Chemical compounds that target thiol-disulfide groups on mononuclear phagocytes inhibit immune mediated phagocytosis of red blood cells
  76. ABO sequence analysis in a family with weak expression of blood group B
  77. Maternal ABO-mismatched blood for intrauterine transfusion of severe hemolytic disease of the newborn due to anti-Rh17
  78. Acute intravascular hemolysis after the infusion of a chimeric red blood cell unit
  79. The structure and function of the molecules that carry human red blood cell and platelet antigens☆
  80. A simple and rapid competitive enzyme-linked immunosorbent assay to identify HPA-1a (PlA1)-negative donor platelet units
  81. Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura
  82. Novel 3' Rhesus box sequences confound RHD zygosity assignment
  83. Synonymous nucleotide substitutions in the neonatal Fc receptor
  84. RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA-based RhD genotype
  85. An Adenine Trimer Precedes a C/G Polymorphism in the 3′-Amplimer Region of the Human Platelet Glycoprotein IIIa Intron 6 CT Repeat
  86. Activation of platelets by sera containing igg1 heparin-dependent antibodies: an explanation for the predominance of the Fcγrlla “low responder” (his131) gene in patients with heparin-induced thrombocytopenia
  87. Maternal immunization to Gov system alloantigens on human platelets
  88. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry
  89. The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis
  90. The cDNA Sequence of Human Endothelial Cell Multimerin
  91. The role of the immunoglobulin heavy chain in human anti-dna antibody binding specificity
  92. Immunoglobulin V Sequences of Two Human Antiplatelet Monoclonal Autoantibodies Derived from B Cells of Normal Origin
  93. Immunoglobulin V region heavy and light chain gene sequences of the lymphoblastoid cell line GM 4672
  94. The production of human monoclonal antiplatelet auto-antibodies derived from human lymphocytes of normal origin: reactivity to DNA, anionic phospholipids and platelet proteins
  95. Comparison of the measurement of surface or total platelet-associated IgG in the diagnosis of immune thrombocytopenia
  96. The production of platelet controls for assays quantitating platelet- associated IgG
  97. Immune-mediated thrombocytopenia of malaria.
  98. The Measurement of Plateiet-Associated IgG Using an Immunoradiometric Assay